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Abstract
Background: Travelers’ diarrhea causes significant morbidity including some sequelae, lost travel time and oppor-
tunity cost to both travelers and countries receiving travelers. Effective prevention and treatment are needed to re-
duce these negative impacts.
Methods: This critical appraisal of the literature and expert consensus guideline development effort asked several
key questions related to antibiotic and non-antibiotic prophylaxis and treatment, utility of available diagnostics, im-
pact of multi-drug resistant (MDR) colonization associated with travel and travelers’ diarrhea, and how our under-
standing of the gastrointestinal microbiome should influence current practice and future research. Studies related to
these key clinical areas were assessed for relevance and quality. Based on this critical appraisal, guidelines were de-
veloped and voted on using current standards for clinical guideline development methodology.
Results: New definitions for severity of travelers’ diarrhea were developed. A total of 20 graded recommendations
on the topics of prophylaxis, diagnosis, therapy and follow-up were developed. In addition, three non-graded con-
sensus-based statements were adopted.
Conclusions: Prevention and treatment of travelers’ diarrhea requires action at the provider, traveler and research
community levels. Strong evidence supports the effectiveness of antimicrobial therapy in most cases of moderate to
severe travelers’ diarrhea, while either increasing intake of fluids only or loperamide or bismuth subsalicylate may
suffice for most cases of mild diarrhea. Further studies are needed to address knowledge gaps regarding optimal
therapies, the individual, community and global health risks of MDR acquisition, manipulation of the microbiome in
Published by Oxford University Press 2017. This work is written by US Government employees and is in the public domain in the US.
Journal of Travel Medicine, 2017, Vol 24, Suppl 1, S63–S80
doi: 10.1093/jtm/tax026
Original Article
Downloaded from https://academic.oup.com/jtm/article-abstract/24/suppl_1/S63/3782742
by Mugar Memorial Library, Boston University user
on 02 November 2017
prevention and treatment and the utility of laboratory testing in returning travelers with persistent diarrhea.
Key words: Clinical practice guideline, emporiatrics, evidence-based medicine
Introduction
Travelers’ diarrhea (TD) has always been, and continues to be,
a problem globally.1 The overall impact of TD is substantial
though it may be declining given the improvements of global
health, sanitation and hygiene.2 Regardless, TD remains a fre-
quent event and can result in many adverse consequences
including lost time and opportunity, changes to itinerary, over-
seas medical encounters and hospitalization.1
Upon discovery that bacterial etiologies were a predominant
cause, the debate surrounding appropriate management has
been evolving and aims to balance safety and efficacy of anti-
microbial therapy. Some of the first randomized controlled
treatment trials demonstrating antibiotic efficacy superior to
placebo were conducted in the early 1980s, with consensus and
expert-based treatment guidelines developed shortly thereafter.3
Studies have also evaluated various antibiotic regimens in com-
bination with loperamide, and randomized controlled trials
(RCT) demonstrate improved efficacy compared to antibiotics
alone when evaluating duration of post-treatment symptoms
and clinical cure.4
While a number of guidelines are currently available which dis-
cuss recommendations around prevention, management and treat-
ment of travelers’ diarrhea,5–11 new data are emerging which may
have an impact on recommendations provided to travelers. These
new issues include emerging data on both the acute and chronic
health consequences of travelers’ diarrhea and treatment, and in
particular the growing recognition of antibiotic resistance acquisi-
tion associated with TD and self-treatment abroad, and the corres-
ponding paramount concern of the impacts on individual and
population health.12,13 Furthermore, advances in technology of
diagnostics, the microbiome and novel therapeutics have brought
new questions and opportunities to the field.14–20
This guideline aims to provide practical guidance to pro-
viders faced with common questions regarding recommenda-
tions on use of antibiotic and non-antibiotic therapies in the
prevention and treatment of TD. We sought to apply a rigorous
process to the review and assessment of evidence and to make
guideline recommendations informed and supported by that evi-
dence. Unfortunately, rigorous data needed to address import-
ant questions in the TD management space are often absent or
insufficient. We therefore present a hybrid document. When suf-
ficiently strong evidence from randomized clinical trials address-
ing a clinically important question is available, we have used
this as a basis to develop our guideline recommendation state-
ments. When evidence is absent or insufficient to provide
evidence-based guidelines, we provide our best expert advice as
consensus statements with the goal of helping providers of all
training levels navigate important management questions.
Methods
The goal of this guideline project was to produce clinically rele-
vant and useful recommendations on management of TD, to be
used by a range of health care providers who provide pre- and
post-travel consultation to travelers. Providers may use these
guidelines to assist with treatment choices that optimize benefits
and minimize harms and burdens associated with this common
acute infection. This guideline also considers other important
aspects of TD, as it relates to the ill returning traveler, the
emerging concern of multi-drug resistant organism (MDRO) ac-
quisition, and current limitations of evidence.
In 2011, the Institute of Medicine (IOM) released new guide-
line standards that required significantly more scientific rigor
and high-quality evidence, as well as a series of processes in
guideline development.21 A highly rigorous and transparent
technical process for evaluating evidence and applying these
evaluations to guideline development, known as GRADE
(Grades of Recommendations, Assessment, Development and
Evaluation), has also been described and continues to evolve.22
The panel supported by the International Society of Travel
Medicine (ISTM) is committed to upholding the IOM standards
in guideline development. However, it should be noted that the
ISTM does not have a formal institutionalized process or dedi-
cated resources for developing clinical practice guidelines. This
project represents panel members’ best attempt to follow the
principles of the GRADE framework and IOM standards, with
limitations as described below. Furthermore, the panel also rec-
ognizes the need to present information that describes good
practice and currently evolving and relevant data, where strong
clinical evidence is either unavailable or not relevant to the ques-
tion under consideration. In such clinical practice scenarios, we
provide guidance in the form of ungraded consensus statements,
accompanied by a summary of the available evidence. When
there is insufficient evidence to make any recommendation, this
has been noted in the text.
Composition and Selection of Panel Members
For this guideline, a Chair was appointed based on experience
in the area of TD. The Chair had the authority, along with
Guideline Organizing Committee (GOC), to nominate other
panelists with experience in relevant areas of TD management.
Conflicts of interest for the panel members were reviewed and it
was determined that disclosure to the panel was necessary, but
did not exclude them for participation in any of the voting. The
panel was made up of 15 voting members, with support from 3
non-voting members.
Identifying and Reviewing the Evidence
Key Questions and Systematic Search: The GOC developed a
list of key clinical questions based on their knowledge of prac-
tice gaps among practitioners managing cases of TD:
1. Should antibiotic prophylaxis be considered for some trav-
elers, and if so, what traveler characteristics should prompt
consideration of prophylaxis and with what agents?
2. What diagnostic modalities should be employed in travelers
with diarrhea and/or persistent abdominal symptoms?
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3. Given growing recognition of MDR colonization in return-
ing travelers, how should travelers be directed with respect
to 1) expectant management, 2) Over-the-counter (OTC)
agents for symptom management, 3) antibiotic use, or 4)
seeking care during travel?
4. In the context of MDR acquisition, how can providers
clearly and effectively convey the risks and benefits of TD
treatment, including acute and chronic consequences and
community risks, when counseling on antibiotic use while
traveling?
5. How does our knowledge (and potential manipulation) of
the microbiome in the setting of TD influence practice rec-
ommendations or future research?
Questions were formulated as explicit or implicit PICO ques-
tions (population of interest, intervention, comparison and out-
come), or related contextual questions which inform the PICO
questions. To inform the evidence around these questions all
panelists were provided with read-ahead materials including
existing TD management guidelines and systematic reviews, key
articles on diagnostics, prophylaxis, and treatment, data on the
influence of travel, diarrhea, antibiotics, diet and the environ-
ment on changes in the gut microbiome, as well as recent data
on MDR organism carriage.1,4,10,14,16,23–41 In addition, prior to
the closed panel session where guidelines were developed, the
ISTM sponsored a 2 day open session Summit Meeting where
experts in the field gave presentations focused on the Key
Clinical Questions identified.
A formal systematic review with data extraction tables de-
tailing all relevant articles for each of the key questions was not
performed. However, the panel did make use of the 2015
Committee to Advise on Tropical Medicine and Travel
(CATMAT) Statement on Travellers’ Diarrhea from the Public
Health Agency of Canada, which had detailed summary tables
on several of Key Clinical Questions, mostly pertaining to
prophylaxis and treatment with antibiotics and non-antibiotic
agents.10 The evidence used for other key clinical questions was
based on the provided read-ahead documents, invited presenta-
tions, and subject matter expertize among panel members.
Drafting Recommendations
The guidelines panel discussion and deliberation was facilitated
by an expert Chairperson in clinical practice and research in
TD. The process for development of each recommendation for a
given key clinical question followed the same algorithm: recom-
mendation formulation, grading the quality of the evidence in
terms of the confidence in the estimates of the efficacy and
harms of the intervention, and grading the strength of the rec-
ommendation based on the balance of harms and benefits, and
knowledge of the values and preferences of travelers. Each of
these steps in the recommendation development and grading uti-
lized the Delphi process including features of anonymity, iter-
ation, controlled feedback and statistical group responses.42
Recommendation Formulation
The entire closed panel participated in the crafting of each of
the recommendation statements. This process was achieved
through the use of a facilitator (the Chair) who posed the key
clinical question and solicited from each of the panelists ideas
on a draft recommendation statement. Points from each of the
panelists were written down on a flip charter and grouped ac-
cordingly. Similar suggestions were grouped together where ap-
propriate. From this process one or more recommendation
statements emerged. A statement would be collectively crafted
and designed to explicitly or implicitly match the PICO format.
When an apparent consensus was reached on the draft recom-
mendation statement, the statement was put to an anonymous
vote by means of a Likert-type question of strongly agree,
weakly agree, weakly disagree, and strongly disagree (using
web-based PollEverywhere.com platform). If there was 80% or
greater agreement (combining votes for strongly agree and
weakly agree), the draft recommendation was accepted and
moved forward for grading of strength and quality of evidence.
In recommendations where there was less than 80% agreement
achieved, the draft recommendation was revisited by discussion,
modified and vote repeated until at least 80% agreement was
achieved. Draft recommendations that could not attain 80%
agreement were abandoned.
Evidence Grading Process for Individual
Recommendations
Upon consensus of each recommendation statement, the panel
considered two dimensions on grading of the evidence. First, the
balance of benefits to harms, risks or burdens, including the
confidence in the estimate of effect (e.g. “net benefit rating”)
was considered. For this assessment, recommendations were
considered “strong” when desirable effects clearly outweighed
the undesirable effects, or vice versa. In the latter case, there
could be a strong negative recommendation (e.g., a strong rec-
ommendation not to use a specific intervention). Strong recom-
mendations (Grade 1) would be phrased using persuasive
language such as “we recommend.” However, when desirable
and undesirable effects were more closely balanced and it was
plausible that the direction or strength of a recommendation
could be changed by patient values and preferences, additional
research information, or other conditions specific to an individ-
ual case, it was graded as “weak”, and statements included
phrasing such as “we suggest.” For a strong recommendation,
where desirable effects were considered to clearly outweigh un-
desirable effects, we judge that most if not all informed service
providers and their clients would choose the intervention. For a
weak recommendation, the variability in provider and client
preference, and tradeoffs between desirable and undesirable
consequences are less clear, we judge that the majority of well-
informed people would want the recommended course of ac-
tion, but a minority (perhaps a large minority) would not.22
The second dimension involved rating of the quality of the
entire body of evidence for each recommendation, in terms of
confidence in the estimates of the effects. The higher the quality
of the evidence, the more likely a strong recommendation is
warranted. GRADE terminology was used for summarizing and
grading the evidence as high, moderate, or low/very low quality.
Ratings of the evidence are evaluated based on criteria of study
design, imprecision, indirectness (relative to the recommenda-
tion statement elements), inconsistency or heterogeneity of re-
sults across studies, and risk of reporting or publication bias. In
general, study designs such as RCTs start as high-quality evi-
dence but are subject to downgrading based on these criteria.
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Observational studies start low but may be upgraded if they
meet design standards and (1) there is a large magnitude of ef-
fect, (2) there is a statistically significant effect even with the
presence of bias, or (3) there is a dose-response gradient. A
grade (high, moderate, or low/very low) was assigned by the
panel to for the quality of evidence supporting each recommen-
dation. A high grade was evidenced from>1 properly RCT that
met most or all of the criteria in terms of quality study design,
precision, directness, consistency and minimized risk of publica-
tion bias. A moderate grade was considered appropriate based
on evidence from>1 well-designed clinical trial, without
randomization or from cohort or case-controlled analytic
studies, from multiple time-series, or from dramatic results from
uncontrolled experiments. A low/very low grade was relegated
to evidence from opinions of respected authorities, based on
clinical experience, descriptive studies, or reports of expert
committees.
For the grading of both the strength of the recommendation
and the quality of evidence ratings, a similar Delphi process was
used to arrive at a consensus grading from the entire voting
panel. For each recommendation, the facilitator would lead the
discussion. Each participant was allowed to summarize his or
her own opinions and thoughts. An anonymous voting method
was used to record participants individual grading categories. If
80% or greater agreement was achieved, the consensus grade
was accepted. If less than 80% agreement was obtained, the fa-
cilitator would lead a re-discussion of the recommendation and
criteria supporting a particular grade, to solicit clarifications
and comments from the panelists. Upon completion of the re-
discussion, another anonymous vote was taken. This process
continued iteratively until at least 80% agreement was attained.
In situations where 80% agreement could not be attained, those
recommendations with grades achieving 67 to 79% agreement
were accepted, but reported with “additional remarks,” which
included a description of the minority opinions and justifica-
tions. Recommendations achieving less than 67% agreement
were not retained.
The committee did not consider the cost of individual treat-
ment or prophylaxis regimens in formulating recommendations.
It is recognized that such consideration is important and de-
pending on different provider, patient and/or payer perspectives,
preferential recommendation choices should be made. Finally,
as described above, some recommendations were not graded by
this process. In such situations, the panel developed an ungraded
consensus-based statement. Consensus in this instance was
determined through open discussion and debate among the
panel, and a draft recommendation put to a consensus vote
required 80% or greater consensus for the recommendation to
be made.
The Chair, co-Chairs and select panelists drafted the initial
manuscript with recommendations combined with the corres-
ponding grades and summary of the evidence. Panelists were
asked to comment and suggest modifications and wording re-
finements. A final consensus document was reviewed and
approved by all panelists.
Review by External Reviewers
When the final manuscript was completed and endorsed by the
GOC, the manuscript underwent peer review process by the
Editorial Board of the Journal of Travel Medicine to consider
content, methods, and adherence to process. Reviewers were
self-nominated and vetted through the Editor-in-Chief, were not
involved in the CPG development process, and included infec-
tious diseases and travel medicine experts.
Recommendations (Table 1)
Travelers’ Diarrhea Definitions
Comment on Definitions
A classification of TD using functional impact for defining se-
verity is advised rather than the traditional frequency-based al-
gorithm that has been utilized.11 If passing numerous stools
represents a functional impairment, it will be judged as more se-
vere than an illness where fewer stools are passed. Previous def-
initions have been variably classified functionally as mild,
moderate or severe or based on number of unformed stools
passed in 24 hours (e.g. 1-2 stools mild, 3-5 stools moderate
and 6-9 stools for severe). Passage of small number of stools
with fever and severe cramps may be more disabling than pas-
sage of six watery diarrheal stools without cramps or pain. We
support an approach that matches the therapeutic intervention
with the severity of illness, in terms of both safety and effective-
ness. Therefore, we recommend definitions based on functional
impact. Prior to travel, the definitions of diarrhea should be dis-
cussed with travelers so they understand when to begin self-
treatment and what treatment modalities should be utilized. It
should be discussed that TD is the sudden onset of abnormally
loose or liquid, frequent stools such that the individual’s assess-
ment is that the illness is tolerable (mild), distressing (moderate)
or incapacitating (severe). It is recognized that this is a departure
from conventional definitions and will bring challenges to the
interpretation and design of future trials related to TD which
have relied on stool frequency-based outcomes; however this
classification system will likely lead to more tailored therapy for
the individual. Further research on defining valid patient-
reported and non-frequency based outcomes in the setting of
TD is needed.
The definition of dysentery should be discussed with future
travelers and is defined as passage of stools that contain gross
blood admixed with stool in the commode and is often accom-
panied by more severe constitutional symptoms including fever.
It should be emphasized that normal appearing stools in the
commode with streaks of blood on the toilet paper may well
represent bleeding haemorrhoids and not dysentery. As most
travelers are unlikely to carry a thermometer to take their tem-
peratures, providers should discuss symptomatology associated
with fever and how fever may alter the assessment of disease
Mild (acute): diarrhea that is tolerable, is not distressing,
and does not interfere with planned activities.
Moderate (acute): diarrhea that is distressing or interferes
with planned activities.
Severe (acute): diarrhea that is incapacitating or com-
pletely prevents planned activities; all dysentery (passage
of grossly bloody stools) is considered severe.
Persistent: diarrhea lasting2 weeks.
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severity. The traveler should be instructed that if their diarrhea
lasts longer than 14 days it is considered persistent diarrhea,
and may be associated with a higher frequency of certain bacter-
ial and protozoal pathogens therefore may justifying evaluation
(see specific recommendations).43 Functional bowel disease
(FBD) may occur after bouts of travelers’ diarrhea and other
enteric infections.44 Many of these former travelers with func-
tional gastrointestinal complaints will meet Rome III or IV
criteria for irritable bowel syndrome (IBS).45 While there are
no recommendations on diagnosis or treatment of IBS or func-
tional gastrointestinal disease after travel, we feel it is import-
ant to recognize this travel associated phenomenon, which is
discussed in relation to a number of the included recommen-
dations in this clinical practice guideline. We offer the follow-
ing definitions to consider post-infectious FBD and IBS in the
returning traveler.
Table 1. Summary of recommendations and statements
Travelers’ diarrhea definitions
Mild (acute): diarrhea that is tolerable, is not distressing, and does not interfere with planned activities.
Moderate (acute): diarrhea that is distressing or interferes with planned activities.
Severe (acute): diarrhea that is incapacitating or completely prevents planned activities; all dysentery (passage of grossly bloody stools) is considered
severe.
Persistent: diarrhea lasting 2 weeks.
Prophylaxis
1. Antimicrobial prophylaxis should not be used routinely in travelers (Strong recommendation, low/very low level of evidence).
2. Antimicrobial prophylaxis should be considered for travelers at high risk of health-related complications of travelers’ diarrhea (Strong recommenda-
tion, low/very low level of evidence).
3. Bismuth subsalicylate (BSS) may be considered for any traveler to prevent travelers’ diarrhea (Strong recommendation, high level of evidence).
4. When antibiotic prophylaxis is indicated, rifaximin is recommended (Strong recommendation, moderate level of evidence).
5. Fluoroquinolones are not recommended for prophylaxis of travelers’ diarrhea (Strong recommendation, low/very low level of evidence).
Therapy of mild travelers’ diarrhea
6. Antibiotic treatment is not recommended in patients with mild travelers’ diarrhea (Strong recommendation, moderate level of evidence).
7. Loperamide or BSS may be considered in the treatment of mild travelers’ diarrhea (Strong recommendation, moderate level of evidence).
Therapy of moderate travelers’ diarrhea
8. Antibiotics may be used to treat cases of moderate travelers’ diarrhea (Weak recommendation, moderate level of evidence).
9. Fluoroquinolones may be used to treat moderate travelers’ diarrhea (Strong recommendation, moderate level of evidence. Qualifying Remarks:
Emergence of resistance to this class of drug though without strong evidence of clinical failure outside of SE Asia, combined with the potential for
adverse dysbiotic (reduction in diversity of intestinal microbiota) and musculoskeletal consequences, contribute important uncertainties to the risk-
benefit assessment and underlie a non-unanimous GRADE of this recommendation).
10. Azithromycin may be used to treat moderate travelers’ diarrhea (Strong recommendation, high level of evidence).
11. Rifaximin may be used to treat moderate travelers’ diarrhea (Weak recommendation, moderate level of evidence). Qualifying Remarks: Caution
should be exercised in provision of rifaximin as empirical therapy of moderate diarrhea in regions or itineraries in which high risk of invasive patho-
gens are anticipated.
12. Loperamide may be used as adjunctive therapy for moderate to severe travelers’ diarrhea (Strong recommendation, high level of evidence).
13. Loperamide may be considered for use as monotherapy in moderate travelers’ diarrhea (Strong recommendation, high level of evidence).
Therapy in severe travelers’ diarrhea
14. Antibiotics should be used to treat severe travelers’ diarrhea (Strong recommendation, high level of evidence).
15. Azithromycin is preferred to treat severe travelers’ diarrhea (Strong recommendation, moderate level of evidence).
16. Fluoroquinolones may be used to treat severe, nondysenteric travelers’ diarrhea (Weak recommendation, moderate level of evidence).
17. Rifaximin may be used to treat severe, nondysenteric travelers’ diarrhea (Weak recommendation, moderate level of evidence).
18. Single-dose antibiotic regimens may be used to treat moderate or severe travelers’ diarrhea (Strong recommendation, high level of evidence).
Follow-up and diagnostic testing
19. Microbiologic testing is recommended in returning travelers with severe or persistent symptoms or in those who fail empiric therapy (Strong recom-
mendation, low/very low level of evidence).
20. Molecular testing, aimed at a broad range of clinically relevant pathogens, is preferred when rapid results are clinically important or non-molecular
tests have failed to establish a diagnosis (ungraded). Qualifying Remarks: No studies have been published as of yet which show that using these tests
improves patient outcomes.
Additional consensus statements (ungraded)
21. There is insufficient evidence to recommend the use of commercially available prebiotics or probiotics to prevent or treat travelers’ diarrhea.
22. Studies are needed on changes in the gut microbiome in travelers with and without diarrhea to clarify the benefits and harms of current and novel
preventive, diagnostic, and therapeutic approaches.
23. There is an incrementally increasing association between travel, travelers’ diarrhea, and antibiotic use with the acquisition of multidrug-resistant
bacteria. Pretravel counseling should include information about this risk, balanced against the benefits of antibiotic use.
Post-infectious irritable bowel syndrome (PI-IBS) and
Functional Bowel Disease (PI-FBD): PI-IBS or PI-FBD are
diagnosed by Rome III or Rome IV criteria after a bout of
TD in a traveler without pre-travel gastrointestinal disease
where the evaluation for microbial etiologies and underly-
ing GI disease is negative.
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Prophylaxis
Summary of the Evidence
There is strong evidence from multiple randomized controlled
trials (RCT) that, depending on compound and destination,
antimicrobials demonstrate prevention of classically defined TD
in about 58 to 88% of travelers.1,26 By contrast, studies demon-
strating the benefit of antimicrobials in primary or secondary
prevention of long-term health consequences that have been
strongly linked to TD36 such as irritable bowel syndrome, react-
ive arthritis, and Guillain-Barre´ syndrome are absent.
Moreover, this cannot be readily inferred from efficacy data
against clinical TD, as subclinical pathogen contact may suffice
to trigger the presumed patho-etiology involved in post-TD
chronic disease morbidity.36 In theory, however, lowering
pathogen burden and limiting mucosal damage through the
prophylactic use of antimicrobials may be anticipated to prevent
long-term morbidity in a fraction of travelers thus justifying
their use in secondary prevention. Indeed, studies in non-
traveler populations have shown that more severe and longer ill-
ness durations are associated with increased risk of post-
infectious IBS,46–49 supporting the notion that prevention of TD
disease (and/or severity and duration) could mitigate the post-
TD chronic health consequences given the similarities of infec-
tion types. Similarly, the rationale of preventing TD-related
complications in chronically ill travelers by prophylactic anti-
microbials has not been subject to rigorous research, but is sup-
ported by clinical reasoning on the vulnerability of certain
patient groups to dehydration and bacteremia.
Against this background, and based on opinion and clinical
expertize, the expert panel gives a strong recommendation in
favor of considering antimicrobials for the prevention of TD in
travelers at high risk of health-related complications. This rec-
ommendation applies to individuals with a desire to travel and a
history of clinically significant long-term morbidity following
an enteric infection (e.g. reactive arthritis) or serious chronic ill-
ness that predisposes for TD-related complications.
At the same time, and also based on opinion and expertize,
the expert panel gives a strong recommendation against the
routine use of antimicrobial prophylaxis for the prevention of
TD in travelers’ sub-groups other than those outlined above.
Antimicrobial resistance has been recognized as a major threat
to health globally and is known to be fostered by antimicrobial
overuse.50 On an individual level, colonization with resistant
bacteria is discussed as potentially harmful consequence of anti-
microbial intake. One cohort study in travelers showed that the
use of antimicrobials at destinations with high-prevalence of
multi-drug resistant organisms (MDROs) in the environment
doubled the risk of intestinal colonization with these bacteria
upon return.25 Together with research from population based
surveillance that found past travel to India to be a risk factor for
infection with MDROs in outpatients,51 these findings point to-
wards a potentially increased risk of infection with MDROs in
travelers using antibiotics as chemoprophylaxis. Further re-
search is needed to clarify the clinical significance of MDRO
colonization in returning travelers who use antimicrobial
chemoprophylaxis.
Other traveler populations which may benefit from anti-
microbials for the prevention of TD but are not explicitly
included in the current panel recommendation have been
described. These include individuals who because of occupation
or itinerary (e.g. athlete in competition, professional musician,
politician, etc.) cannot afford to become sick with TD10 or may
not have access to adequate medical treatment of complicated
TD. Given the rapid effectiveness of antibiotics with or without
loperamide in combination and the increasing threat of anti-
microbial resistance, the rationale supporting the aforemen-
tioned sub-group as populations who might benefit from
antimicrobial chemoprophylaxis may not be as strong anymore.
Therefore, the panel recommends that, when assessing travelers
of this sub-group, travel medicine practitioners take clear public
health responsibility by conducting an individual risk benefit
analysis of antimicrobial chemoprophylaxis vs self-treatment
with self-treatment of moderate to severe TD representing the
standard approach, and chemoprophylaxis the rare exception.
There is strong evidence to recommend the option of using
bismuth subsalicylate (BSS) for prophylaxis of TD in trav-
elers.1,52,53 There have been three sound RCTs using BSS vs pla-
cebo in travelers where BSS was shown to have a strong
protective effect (>60%).54–56 BSS has been studied using either
2.1 g/day or 4.2 g/day in 4 divided doses (with meals and at bed-
time), and has been studied in both the liquid and tablet forms.
A lower dose of 1.05 g/day has also been shown to be prevent-
ive, though it is unclear whether it is as effective as the higher
doses. There are no data on usage of BSS beyond 4 weeks and
no data regarding differences in the liquid form vs the tablet
form. It is unknown what effect BSS may have on the micro-
biome or the acquisition of MDROs. BSS is well tolerated; ad-
verse effects are mild in adults and consist of black tongue,
black stools, tinnitus, potential for constipation, and potential
interference with other medications.56,57 Those who are allergic
to aspirin, who are pregnant, who have chronic renal insuffi-
ciency, and theoretically those who have severe enteric disease
where there may be bismuth absorption should not take BSS.
The panel is aware of the fact that BSS is not available in many
countries.
There is strong evidence to opt for rifaximin in those trav-
elers that require antibiotic prophylaxis. Five RCTs conducted
1. Antimicrobial prophylaxis should not be used routinely
in travelers (Strong recommendation, low/very low level
of evidence).
2. Antimicrobial prophylaxis should be considered for
travelers at high risk of health-related complications of
travelers’ diarrhea (Strong recommendation, low/very low
level of evidence).
3. Bismuth subsalicylate (BSS) may be considered for any
traveler to prevent travelers’ diarrhea (Strong recommen-
dation, high level of evidence).
4. When antibiotic prophylaxis is indicated, rifaximin is
recommended (Strong recommendation, moderate level
of evidence).
5. Fluoroquinolones are not recommended for prophy-
laxis of travelers’ diarrhea (Strong recommendation, low/
very low level of evidence).
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between 2005 and 2013 demonstrated that 200 to 1100 mg of
prophylactic rifaximin per day divided into one to three doses
confer strong protection against TD.58–62 Most enteric patho-
gens causing TD are susceptible to rifaximin63–65 with the ex-
ception of Campylobacter spp. which are resistant.63 This may
explain rifaxmin’s only moderate protective effectiveness in
South and Southeast Asia where Campylobacteriosis is more
common.58 As a non-absorbable antibiotic, rifaximin has an ex-
tremely favorable safety profile. This has been confirmed in tri-
als in traveler58–62 and non-traveler populations.66–68 The
impact of rifaximin prophylaxis on MDRO acquisition has not
been studied. While the number of RCTs to date (N¼5) sup-
porting the recommendation would rate a high level of evidence,
the panel downgraded the strength of evidence for this recom-
mendation due to concerns of unpublished data from at least
one other RCT with rifaximin and to a lesser extent concern
with efficacy in regions where invasive pathogens are more
common.
Four RCTs conducted from 1986 to 1994 demonstrated that
prophylactic fluoroquinolones (FQ) confer strong protection
against classic TD.69–72 Since then, resistance of enteric patho-
gens to FQs has been emerging,65,73,74 reaching 70-80% in
Campylobacter spp. from Nepal and Thailand73,74 and 65% in
ETEC and EAEC from India.65 Hence, the current efficacy of
FQs in preventing TD is unknown, and may be lower than in
these earlier trials. There is also increasing evidence from non-
traveler populations that, in situations where FQs are not essen-
tial, the potential for harm to the peripheral and central nervous
system, tendons, muscles and joints may outweigh the benefit of
their use. This has led to a recent change of the safety labeling
for FQs by the U.S. Food and Drug administration.75 Together
with the known association of FQs with C. difficile-associated
diarrhea,76 these potential harms underline the concern that
FQs should be used with more caution in the TD setting.
Therefore, based on expert opinion, the expert panel does not
recommend FQs for the prophylaxis of TD.
Therapy of Mild Travelers’ Diarrhea
Summary of the Evidence
Increasing concerns on MDRO and the implications on individ-
ual, community and global health, requires the conservation of
antibiotics used in the self-treatment of TD. We recommend an
approach to provide antibiotics for judicious self-treatment to
travelers at risk for TD and counsel them on use according to
the functional impact of symptoms on their travel-related
activities.
The rates of mild illness may vary widely depending on such
factors as the geographic area, type of trip, age of traveler, and
previous exposure; however, a sizeable proportion of illnesses
will fall into the mild category defined as causing little or no
interference in normal daily activities.77–79 For mild diarrhea,
the traveler is encouraged to use supportive measures such as re-
hydration and non-antibiotic, anti-motility drugs such as
loperamide.
The loperamide starting dose is 2 tablets (4 mg), followed by
with uncontrolled diarrhea an additional 2 mg after each add-
itional loose or liquid stool with a total dose of up to 16 mg per
day. Travelers should be counseled that it takes 1 to 2 hours for
loperamide to reach its therapeutic effect, so additional dosing
should be spaced accordingly so as to avoid rebound constipa-
tion. It is important to counsel the traveler that if diarrhea wor-
sens or is accompanied by moderate-severe or invasive
symptoms (e.g. fever, moderate to severe abdominal pain or
bloody diarrhea), then antibiotics should be used.
While dated, the evidence supporting loperamide in treat-
ment of mild TD is strong, and loperamide has an FDA labeled
indication for treatment of mild TD. In a first 1983-84 study
comparing loperamide to bismuth subsalicylate (no placebo), lo-
peramide resulted in fewer unformed stools being passed when
compared to the bismuth subsalicylate treatment group during
the first 48 hours of therapy, though nearly a quarter of volun-
teers opted in for antibiotic rescue therapy.80 Subsequently, in a
RCT of 227 US adults with TD in Mexico, a single high dose of
sulfamethoxazole and trimethoprim (1600/320 mg) or 3 days of
therapy with loperamide hydrochloride (4-mg loading dose,
then 2 mg orally after each loose stool) or sulfamethoxazole-
trimethoprim (800/160 mg orally twice daily), or the combin-
ation of both was evaluated.81 While subjects treated with the
combination had the shortest average duration of diarrhea com-
pared with the placebo group (1 vs 59 hours), loperamide alone
was significantly effective only when treatment failures (13% vs
2% for combination therapy) were treated with antibiotics.
Finally, loperamide was compared to the non-absorbable antibi-
otic, rifaximin, and to the combination of rifaximin plus lopera-
mide for the treatment of TD in a large study of travelers to
Mexico.82 Subjects met a standard definition of TD to be
included in the study and there was no stratification of results
according to illness severity. The mean number of diarrheal
stools in the entire illness was 6.7 for loperamide alone com-
pared to 6.2 for rifaximin and 4.0 for the combination. The
time to last unformed stool was 69 hours for loperamide alone
compared to 33 hours for rifaximin and 27 hours for rifaximin
plus loperamide. None of the subjects treated with loperamide
required treatment with antibiotics. Finally, a number of obser-
vational studies also support treatment of mild diarrhea with
antimotility agents.77,83
No RCTs have been conducted to compare loperamide with
azithromycin or fluoroquinolones (alone or in combination).
Evidence in support of the efficacy of loperamide is stronger than
that for BSS. Other OTC products, such as activated charcoal or
dimenhydrinate, are not recommended. The panel recognizes that
there are other antisecretory agents such as racecadotril, crofe-
lemer and zaldaride which may have a role in travelers’ diarrhea
management. Crofelemer84,85 and zaldaride19,20 have had limited
study in the setting of travelers’ diarrhea, while racecadotril has
not been evaluated in this relevant setting. While crofelemer and
racecadotril are available in many regions of the world, the lack
6. Antibiotic treatment is not recommended in patients
with mild travelers’ diarrhea (Strong recommendation,
moderate level of evidence).
7. Loperamide or BSS may be considered in the treat-
ment of mild travelers’ diarrhea (Strong recommendation,
moderate level of evidence).
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of a labeled indication for use in a travelers’ diarrhea setting, and
no apparent advantage compared to loperamide or BSS, pre-
vented the panel from considering recommendations regarding
these novel anti-secretory agents. We recognize, however, that
there may be a potential use for these agents and encourage future
evaluation alone and in combination with antibiotics for moder-
ate and severe travelers’ diarrhea.
Therapy of Moderate Travelers’ Diarrhea
Summary of the Evidence
There is no question that antimicrobial agents have been dem-
onstrated to be effective in shortening the illness to about one
and a half days,10,52,86 and when combined with loperamide, to
less than one half day.52,87 Even if there were more side effects
as compared to placebo, antimicrobial agents are well tolerated
overall,86 and a movement towards single dose regimens likely
improves the safety profile. In addition, the reduction in the dur-
ation of illness associated with impact on travel with timely and
effective self-treatment will often enable the traveler to continue
the journey as planned. This results not only in stress reduction,
but also may have an economic impact as well. For example, re-
booking flights — sometimes for an entire family — may be
costly and there also may be lost business opportunities.88 It
may be extremely frustrating and ultimately can also have fi-
nancial consequences if a major excursion must be cancelled
because of TD, or if individual travelers are unable to fully
participate in activities for which they may have expended
considerable energy and resources. Furthermore, lack of avail-
ability of empiric therapy may result in the traveler seeking
care from locally, providers which may result in inappropriate,
ineffective and even dangerous care acquired abroad.89,90
On the other hand, antibiotic treatment is not without po-
tential adverse consequences. While adverse events for the com-
monly used antibiotics are rare, they do occur. Most recently,
the FDA released a statement on avoidance of FQ use for non-
complicated bacterial infections due to emerging and accumu-
lating concerns of peripheral neuropathy, central nervous sys-
tem, cardiac, dermatologic effects and hypersensitivity
reactions.91 Although the FQ warning was targeted for non-
complicated upper respiratory tract and urinary infections, and
is likely dose and duration dependent, a lesser concern in treat-
ment of moderate TD is apparent. Particularly in the older trav-
eler, such musculoskeletal and cardiotoxic risks need to be
balanced with the adverse consequences of TD in this popula-
tion who may also be more susceptible to significant dehydra-
tion. In addition, the absolute risk of these rare complications
associated with a single dose regimen is uncertain, but are likely
much lower.
Of growing concern is the demonstration that antibiotic
use in the context of travel (more than travel alone and un-
treated TD alone) is associated with increased rates of acquisi-
tion of ESBL-PE.25,92 These resistant pathogens are usually
not associated with symptoms in the otherwise healthy trav-
eler, carriage is usually transient in duration, and the impact
on the spread of MDRO related infection in the community
and globally is uncertain.23 Nevertheless, their potential im-
portance warrants consideration in balancing the benefit of
acute illness treatment against both individual and population
health consequences. Furthermore, there are increasing con-
cerns about alteration of the individual’s microbiota with anti-
biotic use.16 Use of antibiotics may also be associated with
subsequent C. difficile infection,93 though this has not been
commonly reported in travellers. There are also concerns on
negative effects of antibiotics use (e.g. prolonged carriage) on
enteric infection caused by non-typhoidal Salmonella.94 Here,
as well, single dose antibiotic regimens are likely to minimize
the risk of such consequences; however, data to support an un-
qualified recommendation regarding the advantage of single
dose regimens preventing with respect to these adverse out-
comes are lacking.
One potential value of early and effective treatment of TD
relates to its potential of mitigating the well-described chronic
health consequences of TD, including IBS. The rationale behind
this theoretical benefit relates to the results of a number of epi-
demiological studies, which have identified increased risk of PI-
IBS following longer duration and more severe acute enteric in-
fections.46–49,77,95 Also an animal model demonstrates that co-
administration of an antibiotic (rifaximin) in a rat model miti-
gates the risk of a PI-IBS disease phenotype.96 So far, there have
been no studies assessing whether any use and particularly early
use of effective antibiotics against TD reduces or increases the
risk of sequelae, such research is sorely needed. Thus, taking
into consideration all of the real and theoretical risks and bene-
fits of therapy for moderate TD, we recommend that
8. Antibiotics may be used to treat moderate travelers’
diarrhea (Weak recommendation, moderate level of
evidence).
9. Fluoroquinolones may be used to treat moderate trav-
elers’ diarrhea (Strong recommendation, moderate level
of evidence. Qualifying Remarks: Emergence of resist-
ance to this class of drug though without strong evidence
of clinical failure outside of SE Asia, combined with the
potential for adverse dysbiotic (reduction in diversity of
intestinal microbiota) and musculoskeletal consequences,
contribute important uncertainties to the risk-benefit as-
sessment and underlie a non-unanimous GRADE of this
recommendation).
10. Azithromycin may be used to treat moderate trav-
elers’ diarrhea (Strong recommendation, high level of
evidence).
11. Rifaximin may be used to treat moderate travelers’
diarrhea (Weak recommendation, moderate level of evi-
dence). Qualifying Remarks: Caution should be exercised
in provision of rifaximin as empirical therapy of moderate
diarrhea in regions or itineraries in which high risk of in-
vasive pathogens are anticipated.
12. Loperamide may be used as adjunctive therapy for
moderate to severe travelers’ diarrhea (Strong recom-
mendation, high level of evidence).
13. Loperamide may be considered for use as monother-
apy in moderate travelers’ diarrhea (Strong recommenda-
tion, high level of evidence).
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antibiotics may be used for self-treatment for moderate TD.
Counselling and traveler preferences should also be taken into
consideration.
With respect to antibiotic choice in moderate TD, we have
made a number of class- and regimen-specific recommendations
(Table 2). In nine RCTs, FQs have proven effective against mod-
erate TD.10,52 Widespread resistance has developed mainly in
Southeast and South Asia, particularly against Campylobacter
spp.; thus, these agents are to be avoided in empiric treatment
of moderate or severe TD arising from travel to these areas.1
Observational data also show increasing rates of resistance
elsewhere,97 though studies documenting clinical failures out-
side of SE Asia are not available. These findings, in addition to
some panellists’ concerns about the tendinopathy and dysbiotic
effects of this drug classclass resulted in a non-unanimous
GRADE of this recommendation and the associated qualifying
remarks.
Azithromycin has been evaluated in several RCTs, often in
comparison to FQs for therapy of moderate TD. Studies sup-
port that there are no significant differences in efficacy be-
tween FQs and azithromycin.10 So far there is only limited
resistance to common TD pathogens, but there are concerns in
Nepal,74 and increasing concentrations of drug needed to in-
hibit ETEC and EAEC, which have not yet been shown to
translate into clinical failure.97 Tolerability to azithromycin is
good, but nausea and vomiting are more frequently reported
compared to FQs, particularly when 1,000 mg is ingested as a
single dose.10,98 While there were no increased risks for mor-
tality or cardiovascular events associated with azithromycin
therapy compared to placebo,99,100 sustained ventricular
tachycardia has been observed in patients with prolonged
QTc. This represents a potential risk for certain patient popu-
lations who might have pre-existing conditions or are taking
concomitant medications.101
In two RCTs rifaximin has been found to be a more effective
agent, as compared to placebo, in treating TD associated with
non-invasive pathogens, and in another two RCTs, it has been
shown to be non-inferior to ciprofloxacin.10 So far there are
only limited data on resistance,10 but in contrast to FQs and
azithromycin, there is no indication that MICs increase among
recovered enteric pathogen isolates.65 The safety profile is
excellent with this poorly absorbed agent. So far there is a lack
of documentation as to whether rifaximin therapy is associated
with acquisition of ESBL-PE, but it has been demonstrated to
alter the microbiome, possibly in a beneficial way.102,103
Therefore, rifaximin is recommended as an acceptable alterna-
tive for treatment of moderate TD, however should be used
with caution in areas where invasive pathogens are likely to be
encountered.
Since loperamide is the fastest acting therapeutic against TD,
the rationale of combination therapy with antibiotics is to add
symptomatic relief with curative treatment. Five studies have
shown that the combination of an antibiotic plus loperamide in-
creases the rate of short term cure, whereas in one study utiliz-
ing a FQ in SE Asia where high rates of resistance were known
to occur, no benefit was seen.4,10,52 There is no evidence that
the combined therapy results in increased rates of adverse even-
ts,82 but a secondary analysis of a single observational study
found that combining an antibiotic (of unknown duration and
class) with loperamide was associated with a higher rate of
ESBL-PE recovery from stool samples as compared to the use of
either agent independently.104 Studies evaluating the dysbiotic
and ESBL-PE colonization effects in combined single dose regi-
mens are lacking.
Loperamide may be used as monotherapy for moderate
TD.105 There is unsubstantiated concern of increasing TD pa-
tients’ exposure to pathogens when motility is slowed.
However, numerous studies have demonstrated the effectiveness
of loperamide against TD, among them three travel–related
RCTs comparing loperamide to placebo in settings generally
limited to 3 days.10 It is very well tolerated, except for constipa-
tion, particularly in females, and if there is a lack of adherence
to prescribed dosing instructions.106 In most countries lopera-
mide is contraindicated in children below the age of 2 years. In
children with acute diarrhea between 2 and 11 years of age, lo-
peramide was beneficial without causing severe adverse even-
ts.107 Although there have been few published cases of
significant adverse effects related to empiric use in travelers’ des-
pite very common use of this agent,108 continued use of lopera-
mide alone, or in combination with antibiotics, in the face of
worsening of symptoms or development of dysentery is
cautioned.
Table 2. Acute diarrhea antibiotic treatment recommendations
Antibiotica Dose Treatment duration
Azithromycinc, d 1000 mg by mouth or Single or 1-day dividedb
500 mg by mouth 3 day course
Levofloxacin 500 mg by mouth Single doseb or 3 day course
Ciprofloxacin 750 mg by mouth or Single doseb
500 mg by mouth 3 day course
Ofloxacin 400 mg by mouth Single doseb or 3 day course
Rifaximine 200 mg by mouth three times daily 3 days
aAntibiotic regimens may be combined with loperamide, 4 mg first dose, then 2 mg dose after each loose stool, not to exceed 16 mg in a 24 hour period.
bIf symptoms are not resolved after 24 hours, continue daily dosing for up to 3 days.
cUse empirically as first line in Southeast Asia and India to cover fluoroquinolone resistant Campylobacter or in other geographical areas if Campylobacter or resistant ETEC are
suspected.
dPreferred regimen for dysentery or febrile diarrhea.
eDo not use if clinical suspicion for Campylobacter, Salmonella, Shigella or other causes of invasive diarrhea.
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Therapy in Severe Travelers’ Diarrhea
Summary of the Evidence
The decision to treat TD with non-specific anti-diarrheal medi-
cations and/or an antimicrobial agent is based on assessment of
the severity of illness and the effects it will have on the traveler’s
activities and plans. The classification “severe travelers’ diar-
rhea” includes both severe non-dysenteric watery diarrhea lead-
ing to incapacitation and/or inability to carry out planned
activities, as well as dysentery. It is important to consider the
syndromes separately since their antibiotic management may
differ as detailed in the following summary of evidence.
Antibiotics have been demonstrated to reduce symptom dur-
ation in TD from an average of 50-93 to 16–30 hours.86
Antibiotic therapy has also been demonstrated to be efficacious
in moderate to severe acute bacterial diarrhea in community-
based studies in industrialized countries, and particularly in in-
fections due to Shigella spp. and (early on in the treatment of)
campylobacteriosis (< 72 hours).109–116 An important caveat
when translating the RCT evidence to practice guidance is that
trials include subjects with TD across a range of severity and oc-
casionally exclude individuals with more severe illness such as
dysentery or those in need of hospitalization.
Key considerations in the selection of an empiric antibiotic
include the likelihood of treatment efficacy and rapidity of re-
sponse, regional patterns of probable target pathogens and their
antimicrobial resistance, safety and tolerance profile of the anti-
biotic, simplicity of treatment regimen (and hence patient adher-
ence) and cost. Equivalent efficacy for treatment of watery
noninvasive diarrhea has been demonstrated between FQs (3-
day and single dose), azithromycin (3-day and single dose), and
rifaximin (three times daily for 3 days).117–119 The efficacy of
single dose regimens for both FQs and azithromycin supports
their acceptability (Strong recommendation, high level of
evidence).118,120,121
Azithromycin should be considered the first-line agent in cases
of dysentery (Strong recommendation, high level of evidence) as
well as acute watery diarrhea with greater than mild fever given
the increased likelihood of FQ-resistant Campylobacter, and
other bacterial causes such as Shigella spp., enteroinvasive E. coli,
Aeromonas spp., Plesiomonas spp., and Yersinia enter-
ocolitica.118,122–124 Azithromycin (single 1-gm dose or 500 mg
daily for 3 days) has been shown to be superior to levofloxacin
(500 mg daily for 3 days) in achieving clinical cure in Thailand in
a setting with extremely high rates (exceeding 90%) of FQ-
resistant Campylobacter spp.118 Other randomized trials have
demonstrated equivalent efficacy between azithromycin and FQs;
however, these studies were conducted in areas with TD cases
caused primarily by diarrheagenic E. coli, or in an earlier time
period in Thailand when C. jejuni FQ-resistance rates were sig-
nificantly lower. In those settings, ciprofloxacin treatment failures
requiring rescue therapy did occur (5%) but overall clinical effi-
cacy in post treatment duration was comparable.120,122 FQ-
resistant travel-associated and domestic Campylobacter cases in
industrialized countries have been increasingly reported and are
not restricted to countries such as Thailand, thus leading to the
strong recommendation, high level of evidence recommendation
for azithromycin as first-line dysentery therapy irrespective of
geographic region.125–127 Further support for this is provided by
the emergence of nalidixic acid and FQ resistance in Shigella spp.
and Salmonella spp. from India and in a variety of enteric patho-
gens in sub-Saharan Africa.128–131 Azithromycin has also demon-
strated effective and comparable cure rates with shigellosis,
another common agent causing dysentery.113,132
Azithromycin is generally well tolerated with minimal side ef-
fects, usually dose-related gastrointestinal complaints.133 Incident or
worsening nausea or vomiting are exacerbated by the primary
gastrointestinal infection,134 and are more common than in the
treatment of non-gastrointestinal infections, with rates of 3%
and<1%, respectively.135–138 Comparable efficacy may be achieved
with potentially lower side effect rates, by splitting the single 1-gm
dose over the first day; however, this remains to be proven.
FQs retain efficacy in much of the developing world with the
previous caveats regarding resistance in Campylobacter spp.
and now other enteric pathogens. The recommendation is based
mainly on concerns about reduced benefit due to the likelihood
of FQ-resistant Campylobacter spp., or Shigella spp. being the
cause of dysentery as well as significant risk concerns. FQs are
generally well tolerated, with most adverse effects being mild
and transient. Gastrointestinal (nausea, vomiting, or diarrhea)
and central nervous system (headache, dizziness, or insomnia)
side effects are shared by all quinolones.139 In addition, the FQ
class has several concerns regarding adverse effects including
the potential for Achilles tendon rupture (“black box warning”
issued by US FDA), an increased risk for C. difficile infection,
and rarely the prolongation of the QT interval that may lead to
fatal dysrhythmias.140–142 Consideration should be given to the
potential for drug interactions in a given patient. Recent evi-
dence is accumulating for acquisition of travel-associated gut
dysbiosis as well as MDR bacteria during international trav-
el.16,25,143 The possible potentiating effects of antimicrobials,
particularly FQs, should be factored into the decision to use
these agents for treatment of TD.
Rifaximin, a nonabsorbable antibiotic, has demonstrated
comparable efficacy to FQs in non-invasive TD caused by diar-
rheagenic E. coli.119,144,145 These trials have often excluded pa-
tients with more severe illness, which typically accounts for a
minority of TD cases. Rifaximin is less effective for the treat-
ment of invasive pathogens, with failure to achieve wellness
14. Antibiotics should be used to treat severe travelers’
diarrhea (Strong recommendation, high level of
evidence).
15. Azithromycin is preferred to treat severe travelers’
diarrhea (Strong recommendation, moderate level of
evidence).
16. Fluoroquinolones may be used to treat severe, nondy-
senteric travelers’ diarrhea (Weak recommendation, mod-
erate level of evidence).
17. Rifaximin may be used to treat severe, nondysenteric
travelers’ diarrhea (Weak recommendation, moderate
level of evidence).
18. Single-dose antibiotic regimens may be used to treat
moderate or severe travelers’ diarrhea (Strong recom-
mendation, high level of evidence).
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in up to 50% of the treated subjects.144 As invasive pathogens
such as Campylobacter, Salmonella and Shigella spp. may ac-
count for approximately 10-20% of TD cases, rifaximin cannot
be recommended for areas where these invasive pathogens are
common and it is not appropriate for treatment of dysentery, ir-
respective of illness severity. With the above caveats,
rifaximin has the best safety profile compared to other first-line
antibiotics (Weak recommendation, moderate level of
evidence).
Follow-up and Diagnostic Testing
Summary of the Evidence
Detection and identification of specific etiologic agents may be
helpful for the management and treatment of patients with TD;
however, studies demonstrating the benefit with considerable
cost and clinical practicability challenges are lacking. Therefore,
the recommendations made here are based largely on expert
opinion and clinical judgement. Specifically, it is recommended
that microbiologic diagnosis be attempted in returning travelers
with severe or persistent (chronic) symptoms and if there is
bloody diarrhea or mucus present in the stools. In such cases,
knowing an etiology may assist in directing pathogen-specific
treatment, or withholding antibiotics in the case of a viral eti-
ology being identified. No clinical trials or well-designed obser-
vational studies have been performed to assess the cost-benefit
of a test and treatment strategy in such situations, so clinician
discretion should be used.
While the decision to test is qualified, selection of which
diagnostic test to be performed is also complicated. Due to the
heterogeneity of etiologies, (i.e. bacteria, viruses and parasites),
current microbiological diagnosis requires multiple strategies.
Selective and differential culture media remain the reference
method to isolate bacterial enteropathogens but significant limi-
tations such as low sensitivity and a prolonged turn-around-
time for results may reduce the meaningful impact on a patient’s
management.146 For detection of parasites, microscopic examin-
ation is carried out to detect ova and parasites in stools either
directly from fresh concentrated stools or after staining.
However, this method lacks sensitivity, is time consuming, and
requires highly trained personnel for detection and interpret-
ation. Specific tests for parasite antigen detection, such as
Giardia lamblia, Cryptosporidium spp., or Entamoeba histoly-
tica have also been developed. However, antigen detection tests
can only detect a few specific parasites and therefore cannot
completely replace microscopic examination which detects a
wider variety of pathogens. Antigen detection tests have also
been used to detect some viruses causing gastroenteritis such as
rotavirus and adenovirus; these tests are usually quite specific
and their sensitivity is variable.
In the last decade multi-pathogen molecular-based clinical
assays which can detect a variety of relevant bacteria, viruses
and parasites have been developed which provide the potential
for quick identification and potential impact on treatment deci-
sions.11 The molecular multiplex most studied is xTAGVR
Gastrointestinal Pathogen Panel (GPP) (Luminex Molecular
Diagnostics, Toronto, Canada). This panel detects 15 pathogens,
including nine bacteria, three parasites and three viruses, and has
been evaluated for the diagnosis of diarrhea in different popula-
tions, including travelers. In a study performed to evaluate the
utility of this panel to diagnose TD, it was found that the GPP
test might be especially sensitive for the detection of Shigella,
ETEC and Giardia. However, this panel does not include EAEC
and Cyclospora cayetanensis, two microorganisms responsible
for TD.31 Among other FDA approved multiplex molecular tests
on the market is the FilmArray GI panel (BioFire Diagnostics,
LLC a bioMe´rieux Company, Salt Lake City, UT), which allows
the simultaneous detection of 22 enteropathogens and has the ad-
vantage of being an integrated system requiring only five minutes
of sample handling and providing results in 1 hour.15,147
While these assays have high sensitivity and specificity, the
clinical outcomes advantage and financial impact of these mo-
lecular panels has not yet been fully evaluated, and there are
some concerns that molecular testing may, in some cases, detect
colonization rather than infection. Interpretation therefore may
be difficult and implementation will depend on the economics
of each hospital or clinic system, and perhaps cost-effectiveness
will vary depending on the type of patients tested (pediatric,
hospital or community diarrhea, TD, etc.). Furthermore, the use
of molecular diagnostic methods does not allow for the resist-
ance characterization of etiologies which may be important for
directing care. Thus, the clinician may be in a position of order-
ing both culture-based and molecular tests to be able to fully
evaluate the patient’s illness and identify the best therapy.
Further studies are needed to evaluate the utility of these assays
in a clinical setting of the returning traveler with diarrhea. Until
such studies are conducted, an evidence-based recommendation
for their use cannot be made.
Additional Consensus Statements
19. Microbiologic testing is recommended in returning
travelers with severe or persistent symptoms or in those
who fail empiric therapy (Strong recommendation, low/
very low level of evidence).
20. Molecular testing, aimed at a broad range of clinically
relevant pathogens, is preferred when rapid results are
clinically important or non-molecular tests have failed to
establish a diagnosis (ungraded). Qualifying Remarks: No
studies have been published as of yet which show that
using these tests improves patient outcomes.
21. There is insufficient evidence to recommend the use
of commercially available prebiotics or probiotics to pre-
vent or treat travelers’ diarrhea (ungraded).
22. Studies are needed on changes in the gut microbiome
in travelers with and without diarrhea to clarify the bene-
fits and harms of current and novel preventive, diagnos-
tic, and therapeutic approaches (ungraded).
23. There is an incrementally increasing association be-
tween travel, travelers’ diarrhea, and antibiotic use with
the acquisition of multidrug-resistant bacteria. Pre-travel
counseling should include information about this risk, bal-
anced against the benefits of antibiotic use (ungraded).
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Summary of Evidence
The use of probiotics and prebiotics to prevent or treat acute
diarrheal infection is an appealing concept because of their ease
of use and relative safety. The concept of host resistance to en-
teric infection, also commonly referred to as colonization resist-
ance, describes the microbiota’s capability to prevent and limit
pathogen colonization and growth. Over the past few decades
our understanding of the varied colonization resistance mechan-
isms has expanded to understand key direct and indirect
mechanisms.148,149
While studies assessing probiotic/prebiotic effectiveness in
prevention of acute diarrheal infection in adults have been con-
ducted in the traveler setting,41,150–158 these suffer from vari-
ability in setting, causes of acute diarrhea, probiotic strains,
short follow up and lack of person-time analysis. There are also
large variations in the dosage of probiotics, frequency of admin-
istration and formulations used. Further variation is seen with
regard to timing and administration of these preparations rela-
tive to a number of factors including travel populations and lo-
cations, and concurrent treatment with antimicrobials.150
Although two meta-analyses suggest a marginal benefit of pro-
biotics in prevention of TD, both studies also suggest there is in-
sufficient evidence for extrapolation to global recommendations
for their use.41,150
With regards to a potential treatment indication, a 2010
Cochrane Collaboration systematic review on probiotics and
treatment of intestinal infection identified 63 randomized and
quasi-randomized controlled trials comparing specific probiotic
agent(s) vs placebo or no-treatment for acute diarrhea of pre-
sumed infectious etiology.40 However, only 6 of these trials were
among adults, none of which were in a TD setting though
pathogen-attributable infections described were somewhat com-
parable to common TD etiologies and thus worth consider-
ation.159–164 While one product, Enterococcus LAB SF68,
demonstrated efficacy when examining clinical improvement at 4
days, the theoretical safety concerns raised about this product
limits any further recommendation.165 (Note: Probiotic use for
the treatment of antibiotic associated diarrhea has been recom-
mended).166 For probiotics and prebiotics the challenge has been
to understand the right formulation or combination for the right
condition or individual. In summary, in considering the totality
of evidence, the panel reached a consensus that the data support-
ing the use of probiotics and prebiotics for either a prevention or
treatment indication in TD is not adequate to make a graded rec-
ommendation. More research is needed, however a more thor-
ough knowledge of the host microbiome and mechanisms of
action might be necessary before appropriate trials can be de-
signed using specific agents for prevention and treatment of TD.
For the last three decades, RCTs have consistently and
clearly demonstrated that antibiotics significantly shorten the
duration and alleviate the morbidity of TD which if left un-
treated can last 3 days or more and significantly disrupt travel
plans. Treatment with an effective antibiotic can shorten the
average duration to slightly longer than 1 day, and to less than
one half day if combined with loperamide. However, recently
the concern over antibiotic induced colonization with MDRO
has called into question the role of antibiotics for what is often
is a self-limiting, albeit often disruptive experience. While the
impact to the average traveler of this colonization appears
limited it has been identified as an important fraction of MDRO
urinary tract infections in community and hospital-based
settings.167,168 Carriage appears to be transient, but has been
described to persist in approximately 10% at a year post-travel
and be transmitted to close household contacts.12 The challenge
that we now face as providers is to balance the clear benefits of
individual treatment with the impact of colonization on the
given individual, and in the larger context of risk to close con-
tacts, the community to which the traveler returns, and the glo-
bal spread of resistance. The elderly traveler or the traveler with
a history of recurrent urinary tract infections present a unique
challenge as these individuals may be at higher risk of individual
health consequences from ESBL-PE colonization acquisition,
but also, in case of the elderly or otherwise vulnerable traveler,
the consequences of delayed or untreated illness must be meas-
ured. At a minimum travelers should be made aware of this risk,
and should they become ill following travel, they ought to con-
vey their travel exposure history to their treating providers.
While the role of travelers’ serving as mobility agents of infec-
tious disease and resistance cannot be ignored, the ecology of
ESBL-PE infections is complex and includes important environ-
mental, dietary, migration and local nosocomial transmission
dynamics.30 The expert panel recognizes that the indiscriminant
and overuse of antibiotics in the clinical and livestock settings in
the developing world as a major source of resistance globally,
and the burden of these infection in the developed world is non-
travel associated. ESBL-PE infections are clearly an important
health threat and addressing this complex problem will likely
take a multi-faceted approach. We are then left with considering
what equipoise exists in the balance of treatment vs no treat-
ment in the traveler setting. More evidence is needed. However,
in the interim we recommend discussion with the individual
about the multi-level (individual, community, global) risks of
travel, TD, and the role of antibiotic treatment take place.
Conclusions
The practice of travel medicine is a unique clinical scenario
where we expect the traveler to be the diagnostician, practi-
tioner, and patient when it comes to management of TD. The
translation, conveyance and provision of effective confidence in
the traveler to follow complicated guidelines with various alter-
natives and caveats are an obvious challenge in the already com-
pact interaction in which discussion of other topics such as
vaccines, prevention measures of malaria, and other pre-travel
counseling occurs. Therefore, we attempted to simplify the rec-
ommendations (see Figure 1) into “take home points” which
can guide the provider as well as be discussed with the traveler:
• Most if not all travelers should be provided with loperamide
and an antibiotic for self-treatment.
• If the traveler is going to SE Asia, azithromycin should be
prescribed. A FQ, azithromycin or rifaximin can be used in
all other regions. (Note: if rifaximin given as first-line agent,
azithromycin should also be given in case of dysentery or fe-
brile diarrhea).
• The traveler should be informed that if the illness does not
impact his or her travel, he or she should keep up on fluids
and consider taking loperamide.
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• If the travelers’ illness is having some impact but is tolerable,
they should be instructed to start loperamide and consider
taking a single dose antibiotic for expeditious resolution of
symptoms, while understanding the benefits and risk of anti-
biotics for moderate disease.
• If the travelers’ illness is keeping them in bed or confined to
their room, they should be informed to start antibiotics and
add loperamide if expeditious relief is desired.
• The traveler should be counseled that if symptoms do not
begin to improve within 24 – 36 hours despite self-treatment,
it may be necessary to seek medical attention.
• Prophylaxis should be considered only in high risk groups
(due to underlying health conditions or performance critical
occupation/itinerary) with rifaximin being the first choice
and bismuth subsalicylate as second option (with a reduced
threshold for use).
• If rifaximin is used as prophylaxis, azithromycin should be
provided for standby break-through therapy.
A rational approach of minimizing antibiotic exposure
through use of single dose regimens and selection of a first line
antibiotic agent with less evidence of microbiome disruption
(rifaximin) and resistance colonization may be advised (and
needs immediate further study). Additionally, as travel itself and
untreated TD also increase the individual risk of ESBL-PE col-
onization, non-antibiotic chemoprophylactic strategies, includ-
ing use of bismuth subsalicylate, may decrease both the acute
and post-travel risk concerns. We also recognize that there are
differences in the construct, strength and grading of recommen-
dations of this guideline when compared to the recent American
College of Gastroenterology guideline and CATMAT statement
on the topic of TD treatment, diagnosis and prevention.10,11 We
attribute these differences to factors including the accrual of
new information since the time of these publications, different
methodologies of development, and a dissimilar constitution of
experts involved in guideline development and formulation. The
expert members involved in this guideline were representative of
a broad diversity of country of practice, clinical specialty, and
scientific discipline. Finally, making such calculations and deci-
sions can be a challenge for even the most astute traveler and
added to the anxiety provoked by the onset of that first abdom-
inal cramp and disturbing urgency while traveling in sometimes
austere and inconvenient settings. As such, better and effective
educational methods and tools are needed to help travelers’ pre-
pare for and make the best decisions for each individual.
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